October 3, 2023 - Non-regulatory SynAct Pharma announces additional data from the EXPAND P2b clinical trial further supporting efficacy and activity seen in patients with elevated CRP
August 17, 2023 - Non-regulatory SynAct Pharma completes dosing in part A of combined Phase 2a/b RESOLVE study of resomelagon (AP1189) in rheumatoid arthritis (RA)
July 20, 2023 - Non-regulatory SynAct Pharma completes patient recruitment for part A of combined Phase 2a/b RESOLVE study of resomelagon (AP1189) in rheumatoid arthritis (RA)
July 14, 2023 - Non-regulatory SynAct Pharma announces the completion of dosing in the Phase 2b EXPAND study of resomelagon (AP1189) in early severe rheumatoid arthritis patients
June 29, 2023 - Non-regulatory SynAct Pharma to present at 19th World Congress of Basic and Clinical Pharmacology in Glasgow on July 4
April 17, 2023 - Non-regulatory SynAct Pharma announces program for the upcoming Capital Markets Day in Stockholm on May 5, 2023
March 28, 2023 - Non-regulatory SynAct Pharma to host a Capital Markets Day in Stockholm on May 5, 2023
